Close Menu

NEW YORK – In the Phase I/II LIBRETTO-001 study, 68 percent of 105 heavily pretreated non-small cell lung cancer patients with RET fusions saw their tumors shrink after treatment with Eli Lilly's investigational RET inhibitor selpercatinib, researchers reported today at the World Conference on Lung Cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.